SABCS 2020 | Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes | oncology.medicinematters.com

Medicine Matters Oncology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

14-12-2020 | SABCS 2020 | Conference coverage | Video

Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

Roisin Connolly discusses the next steps following the negative results of the phase 3 ECOG-ACRIN E2112 trial of the HDAC inhibitor entinostat in combination with endocrine therapy in aromatase inhibitor-resistant patients with advanced breast cancer (2:43).

Read transcript

Home
Adis Journal Club
In focus
Browse specialties
About us

Version: 0.2061.0

Medicine Matters Oncology

External Content

New additions to the Adis Journal Club